These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 22773151)

  • 1. Positron emission tomography radiopharmaceutical studies in humans: a guide to regulations for academic researchers.
    Fleming IN; Whelan M; Baxendale R; Gilbert FJ; Matthews PP; Aigbirhio FI
    Nucl Med Commun; 2012 Sep; 33(9):899-906. PubMed ID: 22773151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Positron emission tomography: a clinical and biological research tool].
    Kotzki PO
    J Soc Biol; 2004; 198(2):163-8. PubMed ID: 15368968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011.
    Silberstein EB
    J Nucl Med; 2014 Aug; 55(8):1308-10. PubMed ID: 24876206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
    Hallett WA; Maguire RP; McCarthy TJ; Schmidt ME; Young H
    IDrugs; 2007 Nov; 10(11):791-6. PubMed ID: 17968761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
    Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
    Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast high performance liquid chromatography in PET quality control and metabolite analysis.
    Passchier J
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):411-6. PubMed ID: 19834451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.
    Hart DP; Avivi I; Thomson KJ; Peggs KS; Morris EC; Goldstone AH; Linch DC; Ell PJ; Bomanji JB; Mackinnon S
    Br J Haematol; 2005 Mar; 128(6):824-9. PubMed ID: 15755287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
    Nestle U; Kremp S; Grosu AL
    Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initiation of clinical multicentre studies with local radiotracer production - Regulatory environment and radiopharmaceutical-organisational aspects].
    Zippel C; Neels OC; Hennrich U; Giesel FL; Kopka K
    Nuklearmedizin; 2019 Mar; 58(2):77-85. PubMed ID: 30917396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regulatory Framework for Approval of PET Drug in Korea: A Survey Report].
    Kurihara C; Inoue T
    Kaku Igaku; 2015 Nov; 52(4):341-52. PubMed ID: 27263269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of new regulations for the conduct of clinical trials of investigational medicinal products.
    Bollapragada SS; Norrie JD; Norman JE
    BJOG; 2007 Aug; 114(8):917-21. PubMed ID: 17635485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiopharmacy: regulations and legislations in relation to human applications.
    Decristoforo C; Schwarz SW
    Drug Discov Today Technol; 2011; 8(2-4):e71-7. PubMed ID: 24990265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.
    Aboagye EO; Luthra SK; Brady F; Poole K; Anderson H; Jones T; Boobis A; Burtles SS; Price P
    Br J Cancer; 2002 Apr; 86(7):1052-6. PubMed ID: 11953847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosing.
    Lundqvist H; Antoni G; Långström B
    Eur J Clin Pharmacol; 2007 Jul; 63(7):641-5. PubMed ID: 17457579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.